1450 ET - Americans are struggling to get their hands on branded GLP-1 medications, a hormone that helps regulate blood sugar, appetite, and digestion. Him and Hers, a health and wellness company, said that nearly 80,000 people have reported they can't get access to the drug, especially those in states where obesity is higher. To address this, Him & Hers introduced a GLP-1 supply tracker, allowing users to share their experiences and push for better access. This move could support the company's case for compounded versions of the drug, which the FDA is reviewing. Shares rise 3.7% to $27.67. (kailyn.rhone@wsj.com; @onlykailyn)
(END) Dow Jones Newswires
November 13, 2024 14:50 ET (19:50 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。